Coagulation Analyzers Market Insights, Competitive Landscape and Market Forecast–2026
This report can be delivered to the clients within 7-10 Business Days
Coagulation Analyzers Market By Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents And Consumables), By Test Type (Fibrinogen Testing, Activated Clotting Time Testing (Act), D-Dimer Testing, Platelet Function Testing, Others), By Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), By End-User (Hospitals, Diagnostic Centers, And Others), And By Geography is anticipated to grow at a significant CAGR forecast till 2026 owing to rising prevalence of thromboembolytic disease, bleeding disorders and increase in the availability of more advanced products
Global Coagulation Analyzers Market was valued at USD 4.19 billion in 2020, growing at a CAGR of 5.44% during the forecast period from 2021 to 2026, to reach USD 5.74 billion by 2026. The demand for Coagulation Analyzers is predominantly associated with the rising prevalence of thromboembolytic disease and bleeding disorders such as impaired liver function, hemophilia, and von Willebrand disease. Moreover, the increase in the availability of more advanced analyzers, growing awareness about these diseases and their management, rising geriatric population base are some of the factors likely to boost the Global Coagulation Analyzers Market during the forecast period.
Coagulation Analyzers Market Dynamics:
The Coagulation Analyzers Market has significantly increased owing to the fact that coagulation analysis allows for faster and efficient assessment of blood platelet levels, as well as determining the velocity of different concentrations.
According to the Centers for Disease Control and Prevention 2020, people with hemophilia have unique risk factors that may lead them to heart disease as their life expectancy increases, such as infusion of factor concentrates and infection with HIV. Owing to the growing burden of lifestyle-associated and chronic blood disorders across the globe, the Coagulation Analyzers market has been rising significantly. Similarly, as per Haemophilia Foundation Australia 2021, Haemophilia occurs in 1 in 6,000-10,000 males internationally. According to the same statistics, in Australia, there are more than 3,000 people diagnosed with varying degrees of severity of Haemophilia.
Another factor responsible for the growth of the Coagulation Analyzers market is the prevalence of von Willebrand disease (VWD). As per the Centers for Disease Control and Prevention 2021, VWD is the most common bleeding disorder, found in up to 1% of the US population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease.
Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, and anxiety, financial burden, long-term hospitalization, and even death. Therefore, to properly treat and manage chronic blood disorders like Haemophilia and VWD, Coagulation Analyzers devices are required. These devices help to detect clotting deficiencies, measure coagulation pathways speed, thrombolin levels and are also used to monitor the effects of drugs on whole blood. Since their use is quite extensive and offers wide applications in blood disorders, thus the demand for these devices will grow, which in turn is expected to drive the Global Coagulation Analyzers market.
It is estimated that up to 1% of the world’s population suffers from VWD, but because many people have only very mild symptoms, only a small number of them know they have it. Research has shown that as many as 9 out of 10 people with VWD have not been diagnosed, as per the World Federation of Hemophilia, 2021. Therefore, early detection using coagulation analyzers is very much important and will thereby promote the growth of the global Coagulation Analyzers market.
In addition, key players operating in the market are focusing on developing advanced technologically based Coagulation Analyzers devices and reagents. For instance, in March 2019, HORIBA Medical launched a new Yumizen GDDi 2 (D-Dimer) reagent kit in its hemostasis instrument range, which includes the compact Yumizen G200 coagulation analyzer. The kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). Thus, such development by players may help in contributing to patient management that will augment the demand for Global Coagulation Analyzers and will drive the market growth during the forecasted period from 2021-2026.
Coagulation Analyzers Market Segment Analysis:
Coagulation Analyzers Market by Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), by Test Type (Fibrinogen Testing, Activated Clotting Time Testing (ACT), D-Dimer Testing, Platelet Function Testing, Others), by Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), by End User (Hospitals, Diagnostic Centers, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Coagulation Analyzers product segment, the Automated Analyzers segment is anticipated to hold the largest market share. This is owing to the minimal manual interaction which drastically reduces the chances of infections, errors, rapid precision which ensures reproducibility, reduced personnel to do the task, and most importantly, a large number of samples that can be processed at the same time.
The advantages associated with automated coagulation analyzers are further increasing their demand, thereby driving the growth of the overall Coagulation Analyzers market.
Additionally, a new development in the product lines and new product launches are bolstering the segment growth of the Coagulation Analyzers market during the forecasted period.
North America is expected to dominate the overall Coagulation Analyzers Market:
North America is expected to dominate the overall Coagulation Analyzers market during the forecast period. This domination is owing to the rising prevalence of chronic blood diseases such as Hemophilia and von Willebrand disease. As per the National Hemophilia Foundation 2021, between 30,000- 33,000 people are living with hemophilia in the US.
Additionally, according to CDC 2020, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year in the United States. Thus, the burgeoning cases of diseases will contribute to the growth of the Coagulation Analyzers Market in the region as the demand will increase.
Further, in North America and at the global level the United States represents the largest market worldwide supported by increased awareness about rare diseases and rise in healthcare expenditure by the government owing to the research and development to improve the diagnostic rate and preventive care management among the patients.
Europe and Asia-Pacific region have the future potential growth for the Global Coagulation Analyzers market. This is owing to the rising burden of blood diseases in the European region countries and Asian countries. As per the Haemophilia Foundation Australia, 2021, more than 6,500 people in Australia have been diagnosed with a bleeding disorder.
According to the same statistics, more than 2,300 people have been diagnosed with VWD in Australia, but many more are thought to be undiagnosed. It affects both females and males from all racial backgrounds. Moreover, rising product launch and commercialization agreements among the key manufacturers and other companies are anticipated to boost the Coagulation Analyzers market. For instance, in July 2020, Sysmex launched next-generation fully automated blood coagulation analyzers CN-6000 and CN-3000 in the EMEA region. Such initiatives are anticipated to boost the Coagulation Analyzers Market.
Coagulation Analyzers Market Key Players:
Some of the key market players operating in the Coagulation Analyzers market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation among others.
Recent Developmental Activities in Coagulation Analyzers Market:
In February 2021, Horiba Medical announced that its new generation of the Microsemi CRP hematology analyzer, the Microsemi CRP LC-767G, has received CE marking. The new analyzer is more compact and has enhanced software and network connectivity with higher memory. It also includes a new parameter, the Granulocytes-to-Lymphocytes Ratio.
In January 2021, PixCell Medical announced that it has signed a distribution agreement for its HemoScreen Hematology Analyzer in Sweden with Triolab. HemoScreen is a portable, point-of-care complete blood count analyzer that uses disposable cartridges that include all necessary reagents and provides results from a single drop of blood from a fingerstick.
Key Takeaways from the Coagulation Analyzers Market Report Study
Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Coagulation Analyzers market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the Global Coagulation Analyzers Market.
Various opportunities available for the other competitor in the Coagulation Analyzers Market space.
What are the top performing segments in 2020? How these segments will perform in 2026.
Which is the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Coagulation Analyzers market growth in the coming future?
Target Audience who can be benefited from Coagulation Analyzers Market Report Study
Coagulation Analyzers providers
Research organizations and consulting companies
Coagulation Analyzers-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Coagulation Analyzers market
Various End-users who want to know more about the Coagulation Analyzers Market and latest technological developments in the Coagulation Analyzers market.
Frequently Asked Questions for Coagulation Analyzers Market:
1. What are Coagulation Analyzers?
A Coagulation Analyzer is a device that monitors and evaluates the speed of clot formation or blood coagulation. It aids by identifying the presence of blood clots in the blood vessels to prevent the chances of heart disease, thrombosis, and embolism.
2. What is the market for Global Coagulation Analyzers?
Global Coagulation Analyzers Market was valued at USD 4.19 billion in 2020, growing at a CAGR of 5.44% during the forecast period from 2021 to 2026, to reach USD 5.74 billion by 2026.
3. What are the drivers for Global Coagulation Analyzers?
The major drivers driving the demand for Coagulation Analyzers are the rising prevalence of thromboembolytic disease and bleeding disorders such as impaired liver function, hemophilia, and von Willebrand disease. Moreover, the increase in the availability of more advanced analyzers, growing awareness about these diseases and their management, rising geriatric population base, and increasing funding for research, growth in foreign investments.
4. Who are the key players operating in Global Coagulation Analyzers Market?
Some of the key market players operating in the Coagulation Analyzers market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation among others.
5. Which regions has the highest share in Coagulation Analyzers market?
Among all the other regions, North America is expected to dominate the overall Coagulation Analyzers market during the forecast period. This domination is due to the rising prevalence of chronic blood diseases such as Hemophilia and von Willebrand disease, and technological advancements in this region.
Coagulation Analyzers Market By Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents And Consumables), By Test Type (Fibrinogen Testing, Activated Clotting Time Testing (Act), D-Dimer Testing, Platelet Function Testing, Others), By Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), By End-User (Hospitals, Diagnostic Centers, And Others), And By Geography is anticipated to grow at a significant CAGR forecast till 2026 owing to rising prevalence of thromboembolytic disease, bleeding disorders and increase in the availability of more advanced products
Global Coagulation Analyzers Market was valued at USD 4.19 billion in 2020, growing at a CAGR of 5.44% during the forecast period from 2021 to 2026, to reach USD 5.74 billion by 2026. The demand for Coagulation Analyzers is predominantly associated with the rising prevalence of thromboembolytic disease and bleeding disorders such as impaired liver function, hemophilia, and von Willebrand disease. Moreover, the increase in the availability of more advanced analyzers, growing awareness about these diseases and their management, rising geriatric population base are some of the factors likely to boost the Global Coagulation Analyzers Market during the forecast period.
Coagulation Analyzers Market Dynamics:
The Coagulation Analyzers Market has significantly increased owing to the fact that coagulation analysis allows for faster and efficient assessment of blood platelet levels, as well as determining the velocity of different concentrations.
According to the Centers for Disease Control and Prevention 2020, people with hemophilia have unique risk factors that may lead them to heart disease as their life expectancy increases, such as infusion of factor concentrates and infection with HIV. Owing to the growing burden of lifestyle-associated and chronic blood disorders across the globe, the Coagulation Analyzers market has been rising significantly. Similarly, as per Haemophilia Foundation Australia 2021, Haemophilia occurs in 1 in 6,000-10,000 males internationally. According to the same statistics, in Australia, there are more than 3,000 people diagnosed with varying degrees of severity of Haemophilia.
Another factor responsible for the growth of the Coagulation Analyzers market is the prevalence of von Willebrand disease (VWD). As per the Centers for Disease Control and Prevention 2021, VWD is the most common bleeding disorder, found in up to 1% of the US population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease.
Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, and anxiety, financial burden, long-term hospitalization, and even death. Therefore, to properly treat and manage chronic blood disorders like Haemophilia and VWD, Coagulation Analyzers devices are required. These devices help to detect clotting deficiencies, measure coagulation pathways speed, thrombolin levels and are also used to monitor the effects of drugs on whole blood. Since their use is quite extensive and offers wide applications in blood disorders, thus the demand for these devices will grow, which in turn is expected to drive the Global Coagulation Analyzers market.
It is estimated that up to 1% of the world’s population suffers from VWD, but because many people have only very mild symptoms, only a small number of them know they have it. Research has shown that as many as 9 out of 10 people with VWD have not been diagnosed, as per the World Federation of Hemophilia, 2021. Therefore, early detection using coagulation analyzers is very much important and will thereby promote the growth of the global Coagulation Analyzers market.
In addition, key players operating in the market are focusing on developing advanced technologically based Coagulation Analyzers devices and reagents. For instance, in March 2019, HORIBA Medical launched a new Yumizen GDDi 2 (D-Dimer) reagent kit in its hemostasis instrument range, which includes the compact Yumizen G200 coagulation analyzer. The kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). Thus, such development by players may help in contributing to patient management that will augment the demand for Global Coagulation Analyzers and will drive the market growth during the forecasted period from 2021-2026.
Coagulation Analyzers Market Segment Analysis:
Coagulation Analyzers Market by Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), by Test Type (Fibrinogen Testing, Activated Clotting Time Testing (ACT), D-Dimer Testing, Platelet Function Testing, Others), by Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), by End User (Hospitals, Diagnostic Centers, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Coagulation Analyzers product segment, the Automated Analyzers segment is anticipated to hold the largest market share. This is owing to the minimal manual interaction which drastically reduces the chances of infections, errors, rapid precision which ensures reproducibility, reduced personnel to do the task, and most importantly, a large number of samples that can be processed at the same time.
The advantages associated with automated coagulation analyzers are further increasing their demand, thereby driving the growth of the overall Coagulation Analyzers market.
Additionally, a new development in the product lines and new product launches are bolstering the segment growth of the Coagulation Analyzers market during the forecasted period.
North America is expected to dominate the overall Coagulation Analyzers Market:
North America is expected to dominate the overall Coagulation Analyzers market during the forecast period. This domination is owing to the rising prevalence of chronic blood diseases such as Hemophilia and von Willebrand disease. As per the National Hemophilia Foundation 2021, between 30,000- 33,000 people are living with hemophilia in the US.
Additionally, according to CDC 2020, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year in the United States. Thus, the burgeoning cases of diseases will contribute to the growth of the Coagulation Analyzers Market in the region as the demand will increase.
Further, in North America and at the global level the United States represents the largest market worldwide supported by increased awareness about rare diseases and rise in healthcare expenditure by the government owing to the research and development to improve the diagnostic rate and preventive care management among the patients.
Europe and Asia-Pacific region have the future potential growth for the Global Coagulation Analyzers market. This is owing to the rising burden of blood diseases in the European region countries and Asian countries. As per the Haemophilia Foundation Australia, 2021, more than 6,500 people in Australia have been diagnosed with a bleeding disorder.
According to the same statistics, more than 2,300 people have been diagnosed with VWD in Australia, but many more are thought to be undiagnosed. It affects both females and males from all racial backgrounds. Moreover, rising product launch and commercialization agreements among the key manufacturers and other companies are anticipated to boost the Coagulation Analyzers market. For instance, in July 2020, Sysmex launched next-generation fully automated blood coagulation analyzers CN-6000 and CN-3000 in the EMEA region. Such initiatives are anticipated to boost the Coagulation Analyzers Market.
Coagulation Analyzers Market Key Players:
Some of the key market players operating in the Coagulation Analyzers market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation among others.
Recent Developmental Activities in Coagulation Analyzers Market:
In February 2021, Horiba Medical announced that its new generation of the Microsemi CRP hematology analyzer, the Microsemi CRP LC-767G, has received CE marking. The new analyzer is more compact and has enhanced software and network connectivity with higher memory. It also includes a new parameter, the Granulocytes-to-Lymphocytes Ratio.
In January 2021, PixCell Medical announced that it has signed a distribution agreement for its HemoScreen Hematology Analyzer in Sweden with Triolab. HemoScreen is a portable, point-of-care complete blood count analyzer that uses disposable cartridges that include all necessary reagents and provides results from a single drop of blood from a fingerstick.
Key Takeaways from the Coagulation Analyzers Market Report Study
Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Coagulation Analyzers market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the Global Coagulation Analyzers Market.
Various opportunities available for the other competitor in the Coagulation Analyzers Market space.
What are the top performing segments in 2020? How these segments will perform in 2026.
Which is the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Coagulation Analyzers market growth in the coming future?
Target Audience who can be benefited from Coagulation Analyzers Market Report Study
Coagulation Analyzers providers
Research organizations and consulting companies
Coagulation Analyzers-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Coagulation Analyzers market
Various End-users who want to know more about the Coagulation Analyzers Market and latest technological developments in the Coagulation Analyzers market.
Frequently Asked Questions for Coagulation Analyzers Market:
1. What are Coagulation Analyzers?
A Coagulation Analyzer is a device that monitors and evaluates the speed of clot formation or blood coagulation. It aids by identifying the presence of blood clots in the blood vessels to prevent the chances of heart disease, thrombosis, and embolism.
2. What is the market for Global Coagulation Analyzers?
Global Coagulation Analyzers Market was valued at USD 4.19 billion in 2020, growing at a CAGR of 5.44% during the forecast period from 2021 to 2026, to reach USD 5.74 billion by 2026.
3. What are the drivers for Global Coagulation Analyzers?
The major drivers driving the demand for Coagulation Analyzers are the rising prevalence of thromboembolytic disease and bleeding disorders such as impaired liver function, hemophilia, and von Willebrand disease. Moreover, the increase in the availability of more advanced analyzers, growing awareness about these diseases and their management, rising geriatric population base, and increasing funding for research, growth in foreign investments.
4. Who are the key players operating in Global Coagulation Analyzers Market?
Some of the key market players operating in the Coagulation Analyzers market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation among others.
5. Which regions has the highest share in Coagulation Analyzers market?
Among all the other regions, North America is expected to dominate the overall Coagulation Analyzers market during the forecast period. This domination is due to the rising prevalence of chronic blood diseases such as Hemophilia and von Willebrand disease, and technological advancements in this region.
1. COAGULATION ANALYZERS MARKET REPORT INTRODUCTION
2. COAGULATION ANALYZERS MARKET EXECUTIVE SUMMARY
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1. The United States
3.2. Europe
3.2.1. Germany
3.2.2. France
3.2.3. Italy
3.2.4. Spain
3.2.5. U.K.
3.3. Japan
4. COAGULATION ANALYZERS MARKET KEY FACTORS ANALYSIS
4.1. Coagulation Analyzers Market Drivers
4.1.1. Rising Prevalence of thromboembolytic disease and bleeding disorders
4.1.2. Technological Advancements in the Field of Coagulation Analyzers
4.1.3. Increasing investments and funding by the government
4.1.4. Rising awareness regarding cardiovascular disorders
4.2. Coagulation Analyzers Market Restraints and Challenges
4.2.1. High prices of fully automated coagulation analyzers
4.2.2. Less awareness about hemostasis instruments
4.3. Coagulation Analyzers Market Opportunities
4.3.1. The rise in investment by market players for technological development
4.3.2. Growth Opportunities in Emerging Nations
5. URINARY INCONTINENCE DEVICES PORTER’S FIVE FORCES ANALYSIS
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON URINARY INCONTINENCE DEVICES MARKET
7. COAGULATION ANALYZERS MARKET LAYOUT
7.1. By Product
7.1.1. Instruments
7.1.1.1. Automated Analyzers
7.1.1.2. Semi-Automated Analyzers
7.1.1.3. Manual Analyzers
7.1.2. Reagents And Consumables
7.2. By Test Type
7.2.1. Fibrinogen Testing
7.2.2. Activated Clotting Time Testing (ACT)
7.2.3. D-Dimer Testing
7.2.4. Platelet Function Testing
7.2.5. Others
7.3. By Technology
7.3.1. Optical Technology
7.3.2. Mechanical Technology
7.3.3. Electrochemical Technology
7.3.4. Others
7.4. By End User
7.4.1. Hospitals
7.4.2. Diagnostic Centers
7.4.3. Others
7.5. By Geography
7.5.1. North America
7.5.1.1. North America Coagulation Analyzers Market, by Product
7.5.1.2. North America Coagulation Analyzers Market, by Test Type
7.5.1.3. North America Coagulation Analyzers Market, by Technology
7.5.1.4. North America Coagulation Analyzers Market, by End User
7.5.1.5. North America Coagulation Analyzers Market, by Country
7.5.1.5.1. United States
7.5.1.5.2. Canada
7.5.1.5.3. Mexico
7.5.2. Europe
7.5.2.1. Europe Coagulation Analyzers Market, by Product
7.5.2.2. Europe Coagulation Analyzers Market, by Test Type
7.5.2.3. Europe Coagulation Analyzers Market, by Technology
7.5.2.4. Europe Coagulation Analyzers Market, by End User
7.5.2.5. Europe Coagulation Analyzers Market, by Country
7.5.2.5.1. France
7.5.2.5.2. Germany
7.5.2.5.3. United Kingdom
7.5.2.5.4. Italy
7.5.2.5.5. Spain
7.5.2.5.6. Russia
7.5.2.5.7. Rest of Europe
7.5.3. Asia-Pacific
7.5.3.1. Asia-Pacific Coagulation Analyzers Market, by Product
7.5.3.2. Asia-Pacific Coagulation Analyzers Market, by Test Type
7.5.3.3. Asia-Pacific Coagulation Analyzers Market, by Technology
7.5.3.4. Asia-Pacific Coagulation Analyzers Market, by End User
7.5.3.5. Asia-Pacific Coagulation Analyzers Market, by Country
7.5.3.5.1. China
7.5.3.5.2. Japan
7.5.3.5.3. India
7.5.3.5.4. Australia
7.5.3.5.5. South Korea
7.5.3.5.6. Rest of Asia Pacific
7.5.4. Rest of the World (RoW)
7.5.4.1. RoW Coagulation Analyzers Market, by Product
7.5.4.2. RoW Coagulation Analyzers Market, by Test Type
7.5.4.3. RoW Coagulation Analyzers Market, by Technology
7.5.4.4. RoW Coagulation Analyzers Market, by End User
7.5.4.5. RoW Coagulation Analyzers Market, by Region
7.5.4.5.1. Middle East
7.5.4.5.2. Africa
7.5.4.5.3. South America
8. COAGULATION ANALYZERS GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. COAGULATION ANALYZERS COMPANY AND PRODUCT PROFILES
9.1. Abbott Laboratories Inc.
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4. Product Listing
9.1.5. Entropy
9.2. Siemens Healthcare GmbH
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4. Product Listing
9.2.5. Entropy
9.3. Sysmex Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4. Product Listing
9.3.5. Entropy
9.4. Thermo Fisher Scientific Corporation
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4. Product Listing
9.4.5. Entropy
9.5. F. Hoffmann-La Roche Ltd.
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4. Product Listing
9.5.5. Entropy
9.6. HORIBA Medical
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4. Product Listing
9.6.5. Entropy
9.7. Nihon Kohden Corporation
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4. Product Listing
9.7.5. Entropy
9.8. Maccura Biotechnology Co., Ltd.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4. Product Listing
9.8.5. Entropy
9.9. Bio-Group Medical System
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4. Product Listing
9.9.5. Entropy
9.10. Genrui Biotech Inc.
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4. Product Listing
9.10.5. Entropy
9.11. A&T Corporation
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4. Product Listing
9.11.5. Entropy
9.12. Stago Group
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.13. Beijing Succeeder Technology Inc.
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4. Product Listing
9.13.5. Entropy
9.14. Helena Laboratories Corporation
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4. Product Listing
9.14.5. Entropy
9.15. BPC BioSed S.R.L.
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4. Product Listing
9.15.5. Entropy
9.16. Meril Life Sciences Pvt. Ltd.
9.16.1. Company Overview
9.16.2. Company Snapshot
9.16.3. Financial Overview
9.16.4. Product Listing
9.16.5. Entropy
9.17. SCLAVO Diagnostics International
9.17.1. Company Overview
9.17.2. Company Snapshot
9.17.3. Financial Overview
9.17.4. Product Listing
9.17.5. Entropy
9.18. Erba Group
9.18.1. Company Overview
9.18.2. Company Snapshot
9.18.3. Financial Overview
9.18.4. Product Listing
9.18.5. Entropy
9.19. ACON Laboratories, Inc.
9.19.1. Company Overview
9.19.2. Company Snapshot
9.19.3. Financial Overview
9.19.4. Product Listing
9.19.5. Entropy
9.20. Haemonetics Corporation
9.20.1. Company Overview
9.20.2. Company Snapshot
9.20.3. Financial Overview
9.20.4. Product Listing
9.20.5. Entropy
10. PROJECT APPROACH
10.1. Secondary Sources
10.2. Primary Sources
10.3. Data Triangulation
10.4. Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
2. COAGULATION ANALYZERS MARKET EXECUTIVE SUMMARY
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1. The United States
3.2. Europe
3.2.1. Germany
3.2.2. France
3.2.3. Italy
3.2.4. Spain
3.2.5. U.K.
3.3. Japan
4. COAGULATION ANALYZERS MARKET KEY FACTORS ANALYSIS
4.1. Coagulation Analyzers Market Drivers
4.1.1. Rising Prevalence of thromboembolytic disease and bleeding disorders
4.1.2. Technological Advancements in the Field of Coagulation Analyzers
4.1.3. Increasing investments and funding by the government
4.1.4. Rising awareness regarding cardiovascular disorders
4.2. Coagulation Analyzers Market Restraints and Challenges
4.2.1. High prices of fully automated coagulation analyzers
4.2.2. Less awareness about hemostasis instruments
4.3. Coagulation Analyzers Market Opportunities
4.3.1. The rise in investment by market players for technological development
4.3.2. Growth Opportunities in Emerging Nations
5. URINARY INCONTINENCE DEVICES PORTER’S FIVE FORCES ANALYSIS
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON URINARY INCONTINENCE DEVICES MARKET
7. COAGULATION ANALYZERS MARKET LAYOUT
7.1. By Product
7.1.1. Instruments
7.1.1.1. Automated Analyzers
7.1.1.2. Semi-Automated Analyzers
7.1.1.3. Manual Analyzers
7.1.2. Reagents And Consumables
7.2. By Test Type
7.2.1. Fibrinogen Testing
7.2.2. Activated Clotting Time Testing (ACT)
7.2.3. D-Dimer Testing
7.2.4. Platelet Function Testing
7.2.5. Others
7.3. By Technology
7.3.1. Optical Technology
7.3.2. Mechanical Technology
7.3.3. Electrochemical Technology
7.3.4. Others
7.4. By End User
7.4.1. Hospitals
7.4.2. Diagnostic Centers
7.4.3. Others
7.5. By Geography
7.5.1. North America
7.5.1.1. North America Coagulation Analyzers Market, by Product
7.5.1.2. North America Coagulation Analyzers Market, by Test Type
7.5.1.3. North America Coagulation Analyzers Market, by Technology
7.5.1.4. North America Coagulation Analyzers Market, by End User
7.5.1.5. North America Coagulation Analyzers Market, by Country
7.5.1.5.1. United States
7.5.1.5.2. Canada
7.5.1.5.3. Mexico
7.5.2. Europe
7.5.2.1. Europe Coagulation Analyzers Market, by Product
7.5.2.2. Europe Coagulation Analyzers Market, by Test Type
7.5.2.3. Europe Coagulation Analyzers Market, by Technology
7.5.2.4. Europe Coagulation Analyzers Market, by End User
7.5.2.5. Europe Coagulation Analyzers Market, by Country
7.5.2.5.1. France
7.5.2.5.2. Germany
7.5.2.5.3. United Kingdom
7.5.2.5.4. Italy
7.5.2.5.5. Spain
7.5.2.5.6. Russia
7.5.2.5.7. Rest of Europe
7.5.3. Asia-Pacific
7.5.3.1. Asia-Pacific Coagulation Analyzers Market, by Product
7.5.3.2. Asia-Pacific Coagulation Analyzers Market, by Test Type
7.5.3.3. Asia-Pacific Coagulation Analyzers Market, by Technology
7.5.3.4. Asia-Pacific Coagulation Analyzers Market, by End User
7.5.3.5. Asia-Pacific Coagulation Analyzers Market, by Country
7.5.3.5.1. China
7.5.3.5.2. Japan
7.5.3.5.3. India
7.5.3.5.4. Australia
7.5.3.5.5. South Korea
7.5.3.5.6. Rest of Asia Pacific
7.5.4. Rest of the World (RoW)
7.5.4.1. RoW Coagulation Analyzers Market, by Product
7.5.4.2. RoW Coagulation Analyzers Market, by Test Type
7.5.4.3. RoW Coagulation Analyzers Market, by Technology
7.5.4.4. RoW Coagulation Analyzers Market, by End User
7.5.4.5. RoW Coagulation Analyzers Market, by Region
7.5.4.5.1. Middle East
7.5.4.5.2. Africa
7.5.4.5.3. South America
8. COAGULATION ANALYZERS GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. COAGULATION ANALYZERS COMPANY AND PRODUCT PROFILES
9.1. Abbott Laboratories Inc.
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4. Product Listing
9.1.5. Entropy
9.2. Siemens Healthcare GmbH
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4. Product Listing
9.2.5. Entropy
9.3. Sysmex Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4. Product Listing
9.3.5. Entropy
9.4. Thermo Fisher Scientific Corporation
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4. Product Listing
9.4.5. Entropy
9.5. F. Hoffmann-La Roche Ltd.
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4. Product Listing
9.5.5. Entropy
9.6. HORIBA Medical
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4. Product Listing
9.6.5. Entropy
9.7. Nihon Kohden Corporation
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4. Product Listing
9.7.5. Entropy
9.8. Maccura Biotechnology Co., Ltd.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4. Product Listing
9.8.5. Entropy
9.9. Bio-Group Medical System
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4. Product Listing
9.9.5. Entropy
9.10. Genrui Biotech Inc.
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4. Product Listing
9.10.5. Entropy
9.11. A&T Corporation
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4. Product Listing
9.11.5. Entropy
9.12. Stago Group
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.13. Beijing Succeeder Technology Inc.
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4. Product Listing
9.13.5. Entropy
9.14. Helena Laboratories Corporation
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4. Product Listing
9.14.5. Entropy
9.15. BPC BioSed S.R.L.
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4. Product Listing
9.15.5. Entropy
9.16. Meril Life Sciences Pvt. Ltd.
9.16.1. Company Overview
9.16.2. Company Snapshot
9.16.3. Financial Overview
9.16.4. Product Listing
9.16.5. Entropy
9.17. SCLAVO Diagnostics International
9.17.1. Company Overview
9.17.2. Company Snapshot
9.17.3. Financial Overview
9.17.4. Product Listing
9.17.5. Entropy
9.18. Erba Group
9.18.1. Company Overview
9.18.2. Company Snapshot
9.18.3. Financial Overview
9.18.4. Product Listing
9.18.5. Entropy
9.19. ACON Laboratories, Inc.
9.19.1. Company Overview
9.19.2. Company Snapshot
9.19.3. Financial Overview
9.19.4. Product Listing
9.19.5. Entropy
9.20. Haemonetics Corporation
9.20.1. Company Overview
9.20.2. Company Snapshot
9.20.3. Financial Overview
9.20.4. Product Listing
9.20.5. Entropy
10. PROJECT APPROACH
10.1. Secondary Sources
10.2. Primary Sources
10.3. Data Triangulation
10.4. Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
